Speed-up of approval time for clinic research protocols
The Federal Commissioner of the Mexican Health Authority (COFEPRIS) Mikel Arriola has recently announced that Mexico has become the most competitive Latin American country regarding the approval times for clinic research protocols for new drugs, which have been reduced from three to one month.
This time reduction has been possible due to the collaboration of COFEPRIS with universities, national health institutes and clinical research centers that are authorized as third parties to carry out the assessments.
In August 2015, COFEPRIS signed a collaboration agreement with the Autonomous University of Nuevo León (UANL), which is the first public state university to be authorized for the evaluation of clinic research protocols. UNAL has joined 13 other authorized third parties collaborating with COFEPRIS.
Arriola stated that speeding protocols is expected to increase pharmaceutical industry investment in Mexico.